Compare HG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HG | TNGX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.1B |
| IPO Year | 2023 | 2020 |
| Metric | HG | TNGX |
|---|---|---|
| Price | $38.32 | $21.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $39.86 | ★ $47.00 |
| AVG Volume (30 Days) | 404.0K | ★ 3.6M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | ★ 51.23 | 26.89 |
| EPS | ★ 3.54 | N/A |
| Revenue | ★ $2,905,524,000.00 | $62,384,000.00 |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $2.38 | N/A |
| P/E Ratio | $10.67 | ★ N/A |
| Revenue Growth | 24.70 | ★ 48.29 |
| 52 Week Low | $25.53 | $8.30 |
| 52 Week High | $39.50 | $34.39 |
| Indicator | HG | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.13 | 44.62 |
| Support Level | $33.53 | $20.49 |
| Resistance Level | N/A | $22.01 |
| Average True Range (ATR) | 0.99 | 1.92 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 71.43 | 18.52 |
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.